19123003

Source:http://linkedlifedata.com/resource/pubmed/id/19123003

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005290, umls-concept:C0007131, umls-concept:C0017262, umls-concept:C0185117, umls-concept:C0205195, umls-concept:C0205420, umls-concept:C0281731, umls-concept:C0332293, umls-concept:C0456387, umls-concept:C0817096, umls-concept:C1333355, umls-concept:C1516213, umls-concept:C1522449, umls-concept:C2911684
pubmed:issue	3
pubmed:dateCreated	2009-6-8
pubmed:abstractText	The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs. Class III beta-tubulin is reported to be correlated with resistance to taxanes.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins, http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/Tubulin, http://linkedlifedata.com/resource/pubmed/chemical/beta III-tubulin protein, human, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1432-0843
pubmed:author	pubmed-author:AizawaHisamichiH, pubmed-author:AzumaKoichiK, pubmed-author:HattoriSatoshiS, pubmed-author:IchikiMasaoM, pubmed-author:IkedaJiroJ, pubmed-author:ImamuraYouheiY, pubmed-author:KageMasayoshiM, pubmed-author:KawaharaAkihikoA, pubmed-author:KinoshitaTakashiT, pubmed-author:KuwanoMichihikoM, pubmed-author:SasadaTetsuroT, pubmed-author:TakamoriSinzoS
pubmed:issnType	Electronic
pubmed:volume	64
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	565-73
pubmed:meshHeading	pubmed-meshheading:19123003-Aged, pubmed-meshheading:19123003-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19123003-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:19123003-Cisplatin, pubmed-meshheading:19123003-Combined Modality Therapy, pubmed-meshheading:19123003-DNA-Binding Proteins, pubmed-meshheading:19123003-Disease-Free Survival, pubmed-meshheading:19123003-Drug Resistance, Neoplasm, pubmed-meshheading:19123003-Endonucleases, pubmed-meshheading:19123003-Female, pubmed-meshheading:19123003-Gene Expression Regulation, Neoplastic, pubmed-meshheading:19123003-Humans, pubmed-meshheading:19123003-Immunohistochemistry, pubmed-meshheading:19123003-Lung Neoplasms, pubmed-meshheading:19123003-Male, pubmed-meshheading:19123003-Middle Aged, pubmed-meshheading:19123003-Retrospective Studies, pubmed-meshheading:19123003-Survival Rate, pubmed-meshheading:19123003-Taxoids, pubmed-meshheading:19123003-Tubulin
pubmed:year	2009
pubmed:articleTitle	Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
pubmed:affiliation	Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. azuma@med.kurume-u.ac.jp
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't